argenx to Present at Upcoming Investor Conferences

 

argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that management will present at several upcoming investor conferences in November.

  • Stifel 2017 Healthcare Conference. Chief Scientific Officer, Hans de Haard, will present on Wednesday, November 15, 2017 at 2:45 p.m. ET in New York City.
  • Jefferies 2017 London Healthcare Conference. Chief Executive Officer, Tim Van Hauwermeiren, will present on Thursday, November 16, 2017 at 11:20 a.m. UTC in London.
  • Piper Jaffray 29th Annual Healthcare Conference. Chief Executive Officer, Tim Van Hauwermeiren, will present on Wednesday, November 29, 2017 at 2:30 p.m. ET in New York City.

Live webcasts of the presentations will be available on the Company's website at www.argenx.com. Replays of the webcasts will be availalbe for 90 days following the presentation.

Note

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.
www.argenx.com

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?